<DOC>
	<DOCNO>NCT00295893</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Monoclonal antibody , trastuzumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving combination chemotherapy without trastuzumab surgery may make tumor small reduce amount normal tissue need remove . It yet know whether combination chemotherapy effective without trastuzumab treat breast cancer . PURPOSE : This randomized phase II trial compare two different regimen combination chemotherapy give together without trastuzumab see well work treat patient stage II stage III breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Trastuzumab Treating Patients With Stage II Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare 2 neoadjuvant chemotherapy regimen ( docetaxel , doxorubicin hydrochloride , cyclophosphamide [ TAC ] v doxorubicin cyclophosphamide follow paclitaxel carboplatin [ ACAC ] ) , term toxicity effectiveness define pathological complete remission rate , patient non HER2/neu overexpressing stage II III breast cancer . - Evaluate probability achieve pathological complete remission add trastuzumab ( Herceptin® ) ACAC subset patient HER2/neu overexpressing stage II III breast cancer . Secondary - Identify prognostic predictive marker outcome , recurrence , target therapy . OUTLINE : This randomize study . Patients non HER2/neu overexpressing tumor randomize 1 2 treatment arm . Patients HER2/neu overexpressing tumor assign arm III . - Arm I : Patients receive doxorubicin hydrochloride IV , cyclophosphamide IV , docetaxel IV day 1 . Treatment repeat every 21 day 6 course . - Arm II : Patients receive doxorubicin hydrochloride IV cyclophosphamide IV day 1 ; treatment repeat every 2 week 4 course . Patients receive carboplatin IV day 1 paclitaxel IV day 1 , 8 , 15 ; treatment carboplatin paclitaxel repeat every 4 week 3 course . - Arm III : Patients receive chemotherapy arm II . They also receive trastuzumab ( Herceptin® ) IV weekly , begin first dos paclitaxel carboplatin . Within 4 week completion chemotherapy without trastuzumab ( Herceptin® ) , patient undergo surgery . PROJECTED ACCRUAL : A total 105 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven infiltrate ductal lobular breast carcinoma Stage II III disease Inflammatory breast cancer allow Hormonereceptor status specify PATIENT CHARACTERISTICS : ECOG performance status &lt; 2 Male female Menopausal status specify ( female patient ) Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin normal ( except patient 's Gilbert 's disease ) Creatinine ≤ 1.2 mg/dL Creatinine clearance ≥ 70 mL/min Ejection fraction ≥ 50 % MUGA No neuropathy ≥ grade 1 Not pregnant nursing Negative pregnancy test Fertile patient must use effective nonhormonal contraception No prior malignant disease within past 5 year , exclude : Squamous cell basal cell skin carcinoma Stage I situ cervical carcinoma No noninvasive ( situ ) breast carcinoma within past 5 year PRIOR CONCURRENT THERAPY : At least 5 year since prior antiestrogen treatment indication breast cancer prevention ( tamoxifen , raloxifene , aromatase inhibitor ) No prior radiotherapy chest wall</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>inflammatory breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>Paget disease breast invasive ductal carcinoma</keyword>
	<keyword>invasive ductal breast carcinoma predominant intraductal component</keyword>
	<keyword>invasive ductal breast carcinoma</keyword>
	<keyword>medullary ductal breast carcinoma lymphocytic infiltrate</keyword>
	<keyword>comedo ductal breast carcinoma</keyword>
	<keyword>invasive lobular breast carcinoma predominant situ component</keyword>
	<keyword>invasive lobular breast carcinoma</keyword>
	<keyword>mucinous ductal breast carcinoma</keyword>
	<keyword>papillary ductal breast carcinoma</keyword>
	<keyword>tubular ductal breast carcinoma</keyword>
</DOC>